Stoke Therapeutics Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen

Reuters01-12

Stoke <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen

Stoke Therapeutics Inc. announced updates to the clinical development timeline for its lead investigational medicine, zorevunersen, which is being developed in collaboration with Biogen as a potential disease-modifying treatment for Dravet syndrome. The company now expects to complete enrollment of 150 patients in the Phase 3 EMPEROR study by the second quarter of 2026. A data readout from this study is anticipated in mid-2027 and is expected to support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). Stoke Therapeutics plans to initiate a rolling NDA submission in the first half of 2027. Results from the Phase 3 EMPEROR study have not yet been presented. The company also noted ongoing discussions with the FDA regarding the expedited development and potential registration of zorevunersen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260111172978) on January 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602557201?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602557201","market":"us","top_or_hot":-1,"title":"Stoke Therapeutics Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Stoke Therapeutics Inc. announced updates to the clinical development timeline for its lead investigational medicine, zorevunersen, which is being developed in collaboration with Biogen as a potential disease-modifying treatment for Dravet syndrome. The company now expects to complete enrollment of 150 patients in the Phase 3 EMPEROR study by the second quarter of 2026. A data readout from this study is anticipated in mid-2027 and is expected to support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). Stoke Therapeutics plans to initiate a rolling NDA submission in the first half of 2027. Results from the Phase 3 EMPEROR study have not yet been presented. The company also noted ongoing discussions with the FDA regarding the expedited development and potential registration of zorevunersen.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260111172978) on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stoke Therapeutics Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStoke Therapeutics Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 03:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Stoke Therapeutics Inc. announced updates to the clinical development timeline for its lead investigational medicine, zorevunersen, which is being developed in collaboration with Biogen as a potential disease-modifying treatment for Dravet syndrome. The company now expects to complete enrollment of 150 patients in the Phase 3 EMPEROR study by the second quarter of 2026. A data readout from this study is anticipated in mid-2027 and is expected to support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). Stoke Therapeutics plans to initiate a rolling NDA submission in the first half of 2027. Results from the Phase 3 EMPEROR study have not yet been presented. The company also noted ongoing discussions with the FDA regarding the expedited development and potential registration of zorevunersen.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260111172978) on January 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富兰克林生物科技新领域基金A (acc)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDLLtp8C:1","article_id":"2602557201","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602557201","pubTimestamp":1768158021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Stoke Therapeutics Inc. announced updates to the clinical development timeline for its lead investigational medicine, zorevunersen, which is being developed in collaboration with Biogen as a potential disease-modifying treatment for Dravet syndrome. The company now expects to complete enrollment of 150 patients in the Phase 3 EMPEROR study by the second quarter of 2026. A data readout from this study is anticipated in mid-2027 and is expected to support a New Drug Application  submission to the U.S. Food and Drug Administration . Stoke Therapeutics plans to initiate a rolling NDA submission in the first half of 2027. Results from the Phase 3 EMPEROR study have not yet been presented. The company also noted ongoing discussions with the FDA regarding the expedited development and potential registration of zorevunersen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4588":"碎股","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4585":"ETF&股票定投概念","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","STOK":"Stoke Therapeutics, Inc.","BIIB":"渤健公司","BK4533":"AQR资本管理(全球第二大对冲基金)"},"translate_title":"Stoke Therapeutics加速Dravet综合征药物Zorevunersen的3期EMPEROR研究入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":0.9,"STOK":0.9},"content_text":"Stoke Therapeutics Accelerates Phase 3 EMPEROR Study Enrollment for Dravet Syndrome Drug Zorevunersen\n    \n\n        Stoke Therapeutics Inc. announced updates to the clinical development timeline for its lead investigational medicine, zorevunersen, which is being developed in collaboration with Biogen as a potential disease-modifying treatment for Dravet syndrome. The company now expects to complete enrollment of 150 patients in the Phase 3 EMPEROR study by the second quarter of 2026. A data readout from this study is anticipated in mid-2027 and is expected to support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). Stoke Therapeutics plans to initiate a rolling NDA submission in the first half of 2027. Results from the Phase 3 EMPEROR study have not yet been presented. The company also noted ongoing discussions with the FDA regarding the expedited development and potential registration of zorevunersen.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260111172978) on January 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602557201","isCrawlerRequest":true}